Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Characterize Disease 
to Accelerate Precision Medicine

Our PAD team is your strategic partner for single-cell assay design, sample processing, data analysis and visualization. Whether providing internal services or working with a CRO, we can speed up your success.


Why PAD Services for Therapeutic Development

PAD services are the easiest way to access single-cell insights via the Tapestri platform. 
From understanding therapy resistance mechanisms that are impossible to obtain through traditional methodologies to  precision disease profiling and therapeutic characterization that provide a deeper understanding of the patient journey, PAD services are your link to uniquely insightful, actionable data at any development stage.



Goals: Understanding of the processes and pathways underlying disease, which can provide important insights into potential therapeutic targets and strategies.

Target Identification

Identify specific molecules that play a crucial role in a disease state and ensure that the targets are druggable to produce beneficial and therapeutic effects.

How Tapestri Helps

  • Identify the molecular mechanisms (gene lesions/ surface protein) relevant to disease.
  • Characterize the clonal trajectories involved in tumor development and progression.
  • Dissect the molecular heterogeneity of the target throughout the course of disease to determine if they are correlated with disease exacerbation or progression.
  • Dissect the intratumoral heterogeneity that could lead to cancer adaptation and therapeutic failure.

Target Validation

Goals: Extensive experiments to validate whether modulating the target will result in the desired therapeutic effects.

Lead Discovery & Optimization

Preclinical Dev

HTS to evaluate 10,000 + cpds to identify those that interact with the target.
ID lead cpd/s and optimize for potency and specificity.
Preclinical testing on in vivo animal models to determine the efficacy and safety of the drug, PK/PD, immunogenicity and dosing.

How Tapestri Helps

Target Validation

  • Dissect the molecular heterogeneity and evolution of the target/s in disease models  to determine if they correlate with disease progression.
  • Identify the acquisition of resistance mechanisms that could alter potency of targeted therapies.
  • Confirm that PDX model recapitulate disease from the patient it was derived from.

Lead Discovery & Optimization / Preclinical Dev

  • Measure therapeutic efficiency of agents to ID lead compound.
  • Track genetic and immunophenotypic changes that alter potency of lead compound.

Goals: Clinical trials involve human participants. Provide information on efficacy, safety, PK/PD and dosing and interaction with other drugs.

Phase 1: 20-80 human subjects

Phase 2: 100-300 human subjects

Phase 3: 1000-3000 human subjects

How Tapestri Helps

  • Predictive biomarker screening to identify responders vs non responders and improve patient stratification.
  • Track genetic and immunophenotypic changes to measure therapeutic efficiency and changes that alter potency of lead compound.
  • Predict relapse on remission timepoints.

PAD Proof of 
Concept Study

A look at your samples 
using our single-cell lens

Get a side-by-side comparison of your orthogonal dataset against Tapestri’s 
single-cell multi-omics and see what was missed. Our Proof of Concept Study will allow you to test drive Mission Bio’s innovative technology on a small sample set and experience working with our assay development team, R&D organization, and bioinformatics support.

Our oncology experts partner with you to:
  • Scope your single cell multi-omics 
 project with the goal of uncovering 
 therapeutic resistance
  • Identify high impact longitudinal sample 
 sets that indicate clinical relevance
  • Deliver a comprehensive report that 
 highlights therapeutic insights
  • Deliver next-generation clinical trial 
 design for better patient stratification

Your raw data will be analyzed by expert bioinformaticians and you’ll receive a comprehensive report, summarizing study design and single-cell data interpretation on SNVs, indels, chromosomal rearrangements and CNVs; as well as structural characteristics like zygosity, mutational co-occurrence, and the presence of rare cell populations.

  • Sequencing performance metrics
  • Target panel performance metrics
  • Bulk sequencing data compared with 
 single-cell sequencing
  • Clonal phylogeny
  • SNV and CNV analysis
  • Immunophenotyping & cell lineage
  • UMAP clustering & FISH plots

Driving Success Through PAD Partnership

Get Started

Contact us to begin your evaluation